phase readout
saveNCT06485219: A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
ACTIVE_NOT_RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd. Phase: PHASE2. Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
view source ↗
comments(0)
5-min edit window · permanent after that